SPP1 and liver cancer: The authors showed that the tumor immune barrier created by SPP1+ macrophages interacting with CAFs hinders immune infiltration, and targeting the SPP1 improved the efficacy of anti-PD-1 therapy in the murine model of liver cancer (Figure 2).